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Available online 27 January 2010Abstract The presidential address describes briefly the history of the World Federation for
Vascular Societies (WFVS) and its objectives. Vascular Surgery today includes interventional
procedures (open surgical and endovascular) in addition to risk factor reduction and medical
treatment. It is equally important to train in clinical investigative methods, non-surgical treat-
ment, decision making as is training in technical aspects of interventions. Similarly, it is vital,
that the vascular specialist always recommends the treatment which is best to the individual
patient, not only what he can do or what is best for other reasons, i.e. financial.
Due to the increasing complex procedures - endovascular evolution and what is then ‘‘left’’
for open surgery - specialisation into ‘‘mainly open vascular surgeon’’ and ‘‘mainly endovascu-
lar surgeon’’ preceded by a common basic training into both, seems unavoidable. Similar, in
order to be able to train with relevant case mix and numbers, and in order always to have both
complex open and endovascular skills on call 24 hours per day, 365 days a year, centralisation
into larger units is necessary.
The WFVS is important simply looking at the huge demographic differences throughout the
world. In addition, for introduction of new treatments, training issues and dissemination of
science a global organisation like the WFVS is needed.
ª 2009 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.History and Objectives
The World Federation for Vascular Societies (WFVS) is now 2
years past inauguration; today the European Society for
Vascular Surgery (ESVS) is hosting the third annual meeting.
The inaugural meeting was held in Madrid during the ESVS* Tel.: þ45 35452105; fax: þ45 35452303.
E-mail address: sillesen@mac.com
1078-5884/$36 ª 2009 European Society for Vascular Surgery. Publishe
doi:10.1016/j.ejvs.2009.12.006meeting in September 2007, the second meeting in San
Diego during the annual meeting of the Society for Vascular
Surgery (SVS) in June 2008 and this year we are meeting
here in Oslo.
From the beginning, the WFVS had representation from six
regions: AustraliaeNew Zealand (Australia New Zealand
Society for Vascular Surgery (ANZSVS)), Japan (Japanese
Society for Vascular Surgery (JSVS)), India (Vascular Society of
India (VSI)), South Africa (Vascular Surgical Society of South
Africa (VASSA)), North America (Society European Society ford by Elsevier Ltd. All rights reserved.
Figure 1 President for WFVS Henrik Sillesen at the annual
meeting in Oslo.
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Vascular Surgery (ESVS)). Later, Asia was represented by the
Asian Society for Vascular Surgery (ASVS). Last year South
America was represented by the Brazilian Society for Angiol-
ogy and Vascular Surgery (SBACV), and this year, the Middle
East has joined theWorld Federation. I am happy to announce
the membership of the Orient Society for Vascular Surgery
(OSVS). Each of these regional societies has a councilmember.
The presidency rotates every year and represents the regional
society hosting the forthcoming annualmeeting. I amproud to
have servedas theWFVSpresident 2008e2009with the annual
meeting being held here in Oslo during the annual ESVS
meeting Fig. 1.
The main objectives of the WFVS are to have a platform
for exchange of scientific, educational and political matters
related to management of vascular diseases. Having grown
out of vascular surgical societies, I thinkmost of us, if not all,
realise that vascular surgical procedures are only a part of
treatment of vascular disease. In addition, vascular surgery
and patients suffering from vascular disease do better when
accompanied by good medical treatment. It is interesting to
look back at the past 10e15 years prior to which medical
treatment for vascular disease was recognised mainly as
aspirin and anti-coagulation therapy for some.
What is Vascular Surgery Today?
Invasive interventional procedures, open surgical and
increasingly endovascular alternatives, remain the back-
bone of what we do and train for. However, patient eval-
uation and selection of the right treatment for the
individual patient are increasingly being recognised as vital
for the chance of successful outcome of a procedure. So not
only should we worry about how to train young surgeonstechnically, equally important is training in the decision
processes that precedes surgical planning. That we focus
our training towards the more advanced stages of vascular
disease (e.g., large aneurysms, symptomatic occlusive
atherosclerotic disease and symptomatic venous disease) is
only natural since the earlier stages of vascular diseases in
most cases are easy to treat and can be dealt with in
primary care. More advanced stages need evaluation by
someone who can offer surgical treatment (open as well as
endovascular) when indicated and optimal medical treat-
ment for all e the vascular specialist.
Therefore, training to become a good vascular surgeon
includes training to become a good doctor. Treating
vascular patients includes not only the technical aspects of
the procedure, being it endovascular or open, but it is
equally important to ensure that the treatment offered is
the best for the individual patient, not just what the
attending physician himself is able to perform or what is
most attractive with respect to income. Aggressive medical
therapy has been shown to be very beneficial for our
patients.1e4 Recently, preoperative risk factor reduction
(smoking cessation especially) as well as preoperative
medical treatment has been shown to reduce surgical
morbidity and mortality.5e7 Thus, the issue of vascular
surgeons needing to become vascular specialists is truly
based on evidence showing a benefit to our patients. Rather
than surgeons being someone waiting for other doctors to
refer patients for surgery, we wish to be the experts that
patients are referred to for evaluation of total treatment
needed. I am sure that only few vascular surgeons wish to
end in a situation as cardiac surgeons where cardiologists
decide which patients the cardiac surgeons may operate.
Along the same lines, the ability of the vascular surgeon
(specialist) to perform/evaluate simple and advanced
vascular testing is extremely valuable. This means that we,
during one consultation (i.e., the first), in many cases may
evaluate and investigate the patient and suggest a treatment
plan for the patient. Notmany specialties are able to do that.
Not only is this nice for the patient, but most certainly it also
results in better quality of treatment. Having the same
person evaluating and performing the ultrasound scan (or
someone else working in the vascular laboratory) will ensure
that the findings of the scan will be interpreted rightly
according to the patient symptoms and objective findings.Endovascular treatment
Endovascular treatment has many advantages over open
surgery, provided that outcomes are comparable e and in
many clinical situations, this is the case or almost the case.
For instance, nobody is anymore in doubt that local occlu-
sive disease in the common iliac arteries, in the vast
majority of cases, are best treated with endovascular
techniques. With the increasing use of endovascular tech-
niques, it is only natural that we as vascular surgeons have
had a wish to perform them ourselves. Given that we are
those who evaluate, investigate, make indications, perform
open surgery and perform follow-up in vascular patients,
we also want to be able to do the less invasive interven-
tions. Many vascular surgeons have trained in and now
perform endovascular interventions in addition to open
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many endovascular experts. However, in many countries,
vascular surgeons have only just begun or are still waiting to
begin. In my own country, Denmark, we have had a long-
standing good relationship with interventional radiologists,
who have served us, and our patients, very well. The
backside of this long-standing and good relationship is that
it makes it much more difficult to get into the ‘angio-room’
for us surgeons now. Interventional radiologists do not see
the same need for us to train in endovascular techniques as
we do ourselves (maybe not surprising after all). In
a country where health care and doctors specialisation is
much regulated, we are facing a long process before we will
able to do endovascular interventions on our own. The best
solution would certainly be a merger with those among
interventional radiology who wish to work with vascular
patients! In this manner, all doctors treating vascular
patients could take part in patient evaluation, decision
making on indications, follow-up, etc.
Specialisation within vascular treatment (surgery)
With the development of endovascular procedures now
being able to replace open surgical techniques in many
cases, the need for adjusted training has emerged. Where
vascular surgeons have wished to perform these treat-
ments, they have had to learn doing them and many
countries training programmes for vascular fellows have
changed accordingly. Being able to treat more and more
conditions with endovascular techniques the number of
open surgical procedures to train new vascular surgeons are
becoming less. At the same time, since those procedures
that work best with endovascular management most often
are the least complex, those left for open surgical repair
are the most complex and those that require highest level
are open surgical skills.
In fact, we are facing the dilemma that because endo-
vascular techniques successfully are replacing some, but
not nearly all open surgical procedures, we will need to be
good at both, thus new vascular surgeons will need to train
both. At the same time, the number of cases available to
train has to be divided between the two techniques.
Further challenging, as mentioned, those left for open
surgery are the more complex cases and with least volume,
how do we ensure that we will have good surgeons for those
cases in the future? Sub-specialisation within our specialty
seems the only solution. It is tempting to consider a uniform
basic training in both techniques and later sub-specialisa-
tion into either. In this way, the vascular physician speci-
alised in open surgery could still perform some
endovascular procedures, that is, inflow before a fem-distal
bypass and the endovascular specialist could perform
a complex stent-graft procedure with over-stenting a major
vessel, followed by open surgical revascularisation.
Consequently, when numbers to train need to increase
owing to more treatment alternatives (open and endovas-
cular) larger patient volumes are required. In addition to
the training issues mentioned above, keeping two groups of
specialists with a basic annual volume to retain skills
further adds to the need for centralisation. To have experts
in both open and endovascular techniques available to treat
patients 24 h a day, 365 days a year, we will need tocentralise treatment into larger units. The evolution of
gathering vascular procedures into larger centres is already
happening in many countries not least in Scandinavia (i.e.,
Helsinki, Stockholm and Copenhagen).
What is the Role of the WFVS?
I have already mentioned the main objectives where we can
learn fromeach others challenges and success. Simply looking
at the differences in the presence of vascular surgeons in
different regions reveals enormous differences: in Scandi-
navia, there is one vascular surgeon for every 100 000
inhabitants, in South Africa one per million and in India one
per 3 million. Looking at the scientific aspect, we need to
ensure that new knowledge (evidence of treatment) is
disseminated throughout the world. Even in smaller parts of
the world, we know that evidence may have been provided
for certain treatments years before, yet we fail to implement
them. The impact of worldwide organisations such as the
WFVS might have an additional impact on local/regional
recommendations. Similarly, with development of new
techniques and treatment, we continue to experience prod-
ucts being marketed without evidence for its value. This is,
off course, only natural when a product is new; however,
widespread use by everybody is not warranted. In the
vascular world, we have experienced several cases where
uncontrolled introduction of new technologies or devices in
retrospect were clearly inappropriate (lasers introduced in
the 1990s, early stent grafts in the same period, etc.).
Controlled introduction with inclusion into trials or registries
should bemandatory in such cases and international societies
may play a major role in reminding us all of that, dissemi-
nating data/results, co-ordinating efforts, etc.
Clearly, we cannot bring the annual WFVS meeting to all
regional societies as often aswewould like.With alreadyeight
member-societies, a rotation among all implies how seldom
theWFVScanbepresent in each region.However, it is possible
to bring the WFVS to local arrangements within the member-
societies. For instance, this year the first WFVS symposium
was held in Hyderabad, India, during the annual meeting of
the Indian Vascular Society (IVS) in November 2009.
Conclusion
The WFVS is beginning its third year of existence. It has
grown continuously since inauguration and now covers most
regions in the world. The attendance to our meetings is
increasing rapidly and, in Oslo, we filled the main audito-
rium. In October 2009, we have the first WFVS symposium at
a regional meeting in India. The WFVS is increasingly
becoming recognised and recently the WFVS was invited by
the World Health Organization (WHO) to represent vascular
surgery at the Global Forum for Trauma Care. I would like to
end by thanking you all for letting me serve as president the
past year and I wish the WFVS a great future.
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